Instead, it was driven by the core business and a lower tax rate.

We anticipate a relief rally for pharmaceutical stocks.

It is possible that pharmaceutical group stock momentum could carry (Lilly) higher, but we believe the risk/reward warrants a neutral rating.

Seniors appear to be filling incremental prescriptions, given additional drug coverage.

Managers have a fiduciary reponsibility to utilize all of the available data in a firm to inform decisions

There is no way of keeping profits up but by keeping wages down.